Table 5 PK changes (geometric mean, range) of OLA under DDIs.

From: Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment

Parameters

OLA only (100 mg OD)

OLA + Itraconazole (100 mg OD + 200 mg OD)

Predicteda ratio

Observed ratio

Cmax (ng·mL−1)

2560

3513 (2998–4463)

1.37

1.41

Ctrough (ng·mL−1)

39.1

275.6 (61.7–1450)

7.05

6.56

AUC312–336 (ng·h·mL−1)

14,382

40,931(28,155–67,045)

2.85

2.71

Parameters

OLA only (300 mg OD)

OLA + Rifampin (300 mg OD + 600 mg OD)

Predicted ratio

Observed ratio

Cmax (ng·mL−1)

7818

3878 (2638–5222)

0.50

0.82

Ctrough (ng·mL−1)

115

25(15–324)

0.13

0.05

AUC312–336 (ng·h·mL−1)

52,485

9012 (6268–13,979)

0.17

0.12

  1. aCalculated by ratio of concomitant to only use.